Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150924 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
A Phase 2 study, sponsored by Mineralys Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT06150924 is a Phase 2 study that has completed, run by Mineralys Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT06150924, a Phase 2 study, has completed, sponsored by Mineralys Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor \[ASI\]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB). Subjects will be at least 18 years old with hypertension, and mild to severe CKD with albuminuria at the Screening Visit.
Interventions
- DRUG Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
- DRUG Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2025-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06150924
The ClinicalTrials.gov registry entry for NCT06150924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mineralys Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD is the first listed.
NCT06150924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06150924 about?
NCT06150924 is a clinical study titled "Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria". This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor \[ASI\]) in addition to a SGLT2i for the treatment of hypertension in subjects with...
What is the current status of trial NCT06150924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-12-14. Estimated completion is 2025-04-23.
What interventions are being tested in trial NCT06150924?
The interventions under investigation include: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD (DRUG), Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD (DRUG).
Who is sponsoring clinical trial NCT06150924?
This trial is sponsored by Mineralys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.